Esther Schirrmacher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Esther Schirrmacher has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Ralf Schirrmacher
Division of Oncological Imaging, Department of Oncology, University of Alberta, Edmonton, AB T6G 1Z2, Canada
2 shared publications - Alexey Kostikov
McGill University
1 shared publication Bernd Mathiasch
Institute of Inorganic Chemistry, University of Mainz, Duesbergweg 10‐14, D‐55128 Mainz, Germany
1 shared publication- Björn Wängler
Molecular Imaging and Radiochemistry, Clinic of Radiology and Nuclear Medicine, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany
1 shared publication - Carmen Wängler
Biomedical Chemistry, Clinic of Radiology and Nuclear Medicine, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany
1 shared publication - Christian Fottner
Universitätsmedizin der Johannes Gutenberg-Universitätsmedizin Mainz
1 shared publication
Latest Publications
- Open Access
- 24 July 2014
- Published by Wiley in BioMed Research International
- Vol. 2014, 1-20
18F-Labeled Silicon-Based Fluoride Acceptors: Potential Opportunities for Novel Positron Emitting Radiopharmaceuticals
Background.Over the recent years, radiopharmaceutical chemistry has experienced a wide variety of innovative pushes towards finding both novel and unconventional radiochemical methods to introduce fluorine-18 into radiotracers for positron emission tomography (PET). These “nonclassical” labeling methodologies based on silicon-, boron-, and aluminium-18F chemistry deviate from commonplace bonding of an [18F]fluorine atom (18F) to either an aliphatic or aromatic carbon atom. One method in particular, the silicon-fluoride-acceptor isotopic exchange (SiFA-IE) approach, invalidates a dogma in radiochemistry that has been widely accepted for many years: the inability to obtain radiopharmaceuticals of high specific activity (SA) via simple IE.Methodology.The most advantageous feature of IE labeling in general is that labeling precursor and labeled radiotracer are chemically identical, eliminating the need to separate the radiotracer from its precursor. SiFA-IE chemistry proceeds in dipolar aprotic solvents at room temperature and below, entirely avoiding the formation of radioactive side products during the IE.Scope of Review.A great plethora of different SiFA species have been reported in the literature ranging from small prosthetic groups and other compounds of low molecular weight to labeled peptides and most recently affibody molecules.Conclusions.The literature over the last years (from 2006 to 2014) shows unambiguously that SiFA-IE and other silicon-based fluoride acceptor strategies relying on18F−leaving group substitutions have the potential to become a valuable addition to radiochemistry.
- 24 July 2014
- Published by Wiley in BioMed Research International
- Vol. 2014, 1-20
Open Access18F-Labeled Silicon-Based Fluoride Acceptors: Potential Opportunities for Novel Positron Emitting Radiopharmaceuticals
Background.Over the recent years, radiopharmaceutical chemistry has experienced a wide variety of innovative pushes towards finding both novel and unconventional radiochemical methods to introduce fluorine-18 into radiotracers for positron emission tomography (PET). These “nonclassical” labeling methodologies based on silicon-, boron-, and aluminium-18F chemistry deviate from commonplace bonding of an [18F]fluorine atom (18F) to either an aliphatic or aromatic carbon atom. One method in particular, the silicon-fluoride-acceptor isotopic exchange (SiFA-IE) approach, invalidates a dogma in radiochemistry that has been widely accepted for many years: the inability to obtain radiopharmaceuticals of high specific activity (SA) via simple IE.Methodology.The most advantageous feature of IE labeling in general is that labeling precursor and labeled radiotracer are chemically identical, eliminating the need to separate the radiotracer from its precursor. SiFA-IE chemistry proceeds in dipolar aprotic solvents at room temperature and below, entirely avoiding the formation of radioactive side products during the IE.Scope of Review.A great plethora of different SiFA species have been reported in the literature ranging from small prosthetic groups and other compounds of low molecular weight to labeled peptides and most recently affibody molecules.Conclusions.The literature over the last years (from 2006 to 2014) shows unambiguously that SiFA-IE and other silicon-based fluoride acceptor strategies relying on18F−leaving group substitutions have the potential to become a valuable addition to radiochemistry.
- 28 February 2006
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes
- Vol. 114 (S 1) , OR4_19
In vivo-molecular and morphological imaging of somatostatin receptors by real time confocal mini-microscopy
Objective: Expression of somatostatin-receptors (sstr) in neuroendocrine tumors represent the molecular basis for various clinical diagnostic and therapeutic applications. The aim of the current study was to evaluate in-vivo molecular imaging of sstr using real time confocal mini microscopy (CMM) in conjunction with fluorescent labelled octreotate. Methods: CMM was performed using a small rigid probe with an outer diameter of 7mm and an integrated single line laser (488 nm). Fluorescein labeled octreotate (OcF) was synthesized via Fmoc solid phase peptide synthesis. For in-vitro evaluation of OcF, ssstr-expressing exocrine rat pancreatic cancer cells (AR42J) were used. For in-vivo experiments, confocal images of rat pancreas and solid sstr-expressing tumors, induced after subcutaneous injection of AR42J cells into nude mice, were collected following bolus intravenous injection of OcF (15µg/g). Results: Incubation of AR42J cells with OcF showed a time- and dose dependent staining of the cells. Binding specificity could be demonstrated by adding excess amount of unlabeled octreotide, showing an almost complete displacement of OcF. After systemic application to rats, an internalization and homogenous cytoplasmic distribution into pancreatic islet cells was recorded after an incubation time of 30–45 minutes, representing sstr-positive islet cells as correlated with the histological examination. Molecular targeting of sstr-positive tumor-cells in-vivo was demonstrated after application of OcF to tumor expressing nude mice. Tumor cells displayed a cell surface and cytoplasmic staining and OcF-binding and uptake occurred in a patchy pattern, indicating that somatostatin receptors were not regularly distributed among tumor cells, as confirmed by ex-vivo immunohistochemistry. Conclusion: CMM with fluorescein labeled octreotate allows real time in-vivo molecular, functional and morphological imaging of sstr-expressing cell structures and, since it is applicable to humans, will permit specific molecular imaging of sstr during ongoing gastrointestinal endoscopy.
- 28 February 2006
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes
- Vol. 114 (S 1) , OR4_19
In vivo-molecular and morphological imaging of somatostatin receptors by real time confocal mini-microscopy
Objective: Expression of somatostatin-receptors (sstr) in neuroendocrine tumors represent the molecular basis for various clinical diagnostic and therapeutic applications. The aim of the current study was to evaluate in-vivo molecular imaging of sstr using real time confocal mini microscopy (CMM) in conjunction with fluorescent labelled octreotate. Methods: CMM was performed using a small rigid probe with an outer diameter of 7mm and an integrated single line laser (488 nm). Fluorescein labeled octreotate (OcF) was synthesized via Fmoc solid phase peptide synthesis. For in-vitro evaluation of OcF, ssstr-expressing exocrine rat pancreatic cancer cells (AR42J) were used. For in-vivo experiments, confocal images of rat pancreas and solid sstr-expressing tumors, induced after subcutaneous injection of AR42J cells into nude mice, were collected following bolus intravenous injection of OcF (15µg/g). Results: Incubation of AR42J cells with OcF showed a time- and dose dependent staining of the cells. Binding specificity could be demonstrated by adding excess amount of unlabeled octreotide, showing an almost complete displacement of OcF. After systemic application to rats, an internalization and homogenous cytoplasmic distribution into pancreatic islet cells was recorded after an incubation time of 30–45 minutes, representing sstr-positive islet cells as correlated with the histological examination. Molecular targeting of sstr-positive tumor-cells in-vivo was demonstrated after application of OcF to tumor expressing nude mice. Tumor cells displayed a cell surface and cytoplasmic staining and OcF-binding and uptake occurred in a patchy pattern, indicating that somatostatin receptors were not regularly distributed among tumor cells, as confirmed by ex-vivo immunohistochemistry. Conclusion: CMM with fluorescein labeled octreotate allows real time in-vivo molecular, functional and morphological imaging of sstr-expressing cell structures and, since it is applicable to humans, will permit specific molecular imaging of sstr during ongoing gastrointestinal endoscopy.
- 6 August 2003
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 46 (10) , 959-977
Syntheses of novel N‐([18F]fluoroalkyl)‐N‐nitroso‐4‐methyl‐benzenesulfonamides and decomposition studies of corresponding 19F‐ and bromo‐analogues: potential new compounds for the 18F‐labelling of radiopharmaceuticals
- 6 August 2003
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 46 (10) , 959-977
Syntheses of novel N‐([18F]fluoroalkyl)‐N‐nitroso‐4‐methyl‐benzenesulfonamides and decomposition studies of corresponding 19F‐ and bromo‐analogues: potential new compounds for the 18F‐labelling of radiopharmaceuticals